SPONSORS

Australasia – the Pulmonary Fibrosis trial-ready destination

Why Australia and New Zealand?

Australasia’s clinical trials infrastructure, streamlined regulatory approval system along with available grants and incentives makes us a competitive clinical trials destination.

In relation to PF, we also have:

  • A close-knit network of world-leading, experienced PF investigators united through PACT.
  • A proven track record of outstanding recruitment to the world’s largest PF clinical trials.
  • Unsurpassed network of Interstitial Lung Disease Multi-Disciplinary Meetings with standardised diagnostic algorithms.
  • A receptive market for the development of genomics and precision medicine.
  • A thriving research ecosystem.
  • Australia’s Research and Development Tax Credit Scheme, click here.
  • Australia’s clinical trial notification scheme streamlines early phase drug development, click here.
  • Multi-site HREC/IRB approvals processes, find out more via NHMRC or Bellberry.